Oncorus

$12.74 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Oncorus

Oncorus, Inc. is a clinical stage biopharmaceutical company focused on developing viral immunotherapies for cancer patients. The Company is leveraging its platforms to develop a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. The Company is developing a differentiated portfolio of locally and systemically administered oncolytic virus therapies across its oncolytic Herpes Simplex Virus (oHSV) and Synthetic Virus Platform. Its lead product candidates are ONCR-177, ONCR-GBM, Synthetic Coxsackievirus (CV)A21 and Synthetic Seneca Valley Virus (SVV).

Stock Analysis

last close $13.03
1-mo return -15.7%
3-mo return -10.6%
avg daily vol. 183.5T
52-week high 37.86
52-week low 11.5
market cap. $334M
forward pe -
annual div. -
roe -166.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 78.1%
baraka

Subscribe now for daily local and international financial news

Subscribe